首页ALMKT • EPA
add
Mauna Kea Technologies SA
市场资讯
财务信息
损益表
收入
净收入
| (EUR) | 2024年6月info | 年同比变化 |
|---|---|---|
收入 | 213.45万 | -40.22% |
经营支出 | 350.55万 | -5.78% |
净收入 | -234.30万 | -267.42% |
净利润率 | -109.77 | -380.03% |
每股收益 | — | — |
息税折旧摊销前利润 | -176.30万 | -559.07% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (EUR) | 2024年6月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 381.70万 | -39.56% |
总资产 | 1814.60万 | -25.14% |
负债总额 | 3849.00万 | -5.23% |
权益总额 | -2034.40万 | — |
发行在外的股份 | 6461.75万 | — |
市净率 | -0.57 | — |
资产回报率 | -25.45% | — |
资本回报率 | -56.78% | — |
现金流
现金净变动
| (EUR) | 2024年6月info | 年同比变化 |
|---|---|---|
净收入 | -234.30万 | -267.42% |
来自运营的现金 | -190.20万 | -233.29% |
投资现金 | 3.65万 | 183.91% |
融资现金 | -22.65万 | -218.90% |
现金净变动 | -208.55万 | -232.96% |
自由现金流 | -80.29万 | -487.16% |
简介
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
CEO
成立时间
2000
员工数量
65
